Alfuzosin hydrochloride NDC 29300-155

NDC codes

FDA NDC Directory

Product NDC (as listed)29300-155Labeler and product segments. Claims need a package NDC.

Product NDC at billing width29300-0155Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
29300-155-01	29300015501	100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (29300-155-01)Marketed from Mar 15, 2016
29300-155-13	29300015513	30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (29300-155-13)Marketed from Mar 15, 2016
29300-155-19	29300015519	90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (29300-155-19)Marketed from Mar 15, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alfuzosin hydrochloride
Generic name (nonproprietary): alfuzosin hydrochloride
Active ingredients: Alfuzosin hydrochloride — 10 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Unichem Pharmaceuticals (USA), Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203192
Marketing start: Mar 15, 2016
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 29300-155_8190595a-be8e-4fd0-bcdf-30b6ba64ef5aSPL ID 8190595a-be8e-4fd0-bcdf-30b6ba64ef5aSPL set ID 644295a9-75cb-4326-a71f-b0f4e0c4cf75RxCUI 861132UNII 75046A1XTN
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N429300015501 followed by a unit qualifier and the quantity

Package 29300-0155-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 25, 2022.

Indications (excerpt from the label)

Alfuzosin hydrochloride extended-release tablets, USP, an alpha adrenergic antagonist, are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. ( 1 ) Important Limitations of Use: Alfuzosin hydrochloride extended-release tablets, USP are not indicated for treatment of hypertension. ( 1.1 ) Alfuzosin hydrochloride extended-release tablets, USP are not indicated for use in pediatric population. ( 1.1 , 8.4 , 12.3 ) Alfuzosin hydrochloride extended-release tablets, USP are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. 1.1 Important Limitations of Use Alfuzosin hydrochloride extended-release tablets, USP are not indicated for the…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203192

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203192
Product	Strength	Form · route	Labeler	Product NDC
Alfuzosin hydrochloride	Alfuzosin hydrochloride 10 mg/1	Tablet, Extended releaseOral	Northwind Health Company, LLC	51655-967
Alfuzosin hydrochloride	Alfuzosin hydrochloride 10 mg/1	Tablet, Extended releaseOral	Bryant Ranch Prepack	63629-9155